CD44 and cancer: In this regard, CD44s is overexpressed in mesenchymal stem-like cancer cells, but it is also expressed at various levels in non-cancer cell types [11], which could present a clinical challenge for anti-CD44 therapies due to a potential on-target toxicities in healthy tissues.